Abstract：
To overcome the COVID-19 pandemic, the development of safe and effective vaccines is crucial. With the enormous information available on vaccine development for COVID-19, there are still grey areas to be considered when designing a potential vaccine. The rapid regulatory approval of nucleic acid-based vaccines was unique to the COVID-19; these vaccines were rapidly produced cost-effectively and with lesser risk of infectivity. Additionally, they demonstrated relative stability at room temperature (DNA). However, a comparative understanding of the immunogenic impact and efficacy of these vaccines is lacking. Immunogenicity is essential for developing and maintaining effective and long-lasting post-vaccination immunity to pathogenic microorganisms. This systematic review aims to assess and summarize the immunogenicity and protective efficacy of the nucleic acid-based vaccines against COVID-19. The Preferred Reporting Items for Systematic Reviews (PRISMA) recommendations were followed in this review. CASP tool was used for quality assessment of randomized controlled trials. All included studies employed a randomized control method, and the results demonstrated promising immune responses and effectiveness that provided high-level protection against COVID-19 infection. This study offers vital insights for advancing vaccine technology. Furthermore, it guides formulation, informs personalized vaccination strategies, and enhances global health preparedness, particularly in regions with limited vaccine access.
摘要：
为了克服COVID-19大流行，开发安全有效的疫苗至关重要。由于有关COVID-19疫苗开发的大量信息，在设计潜在疫苗时仍有灰色地带需要考虑。基于核酸的疫苗的快速批准是COVID-19所独有的；这些疫苗的快速生产具有成本效益，感染性风险较低。此外,它们在室温下表现出相对稳定性(DNA)。然而,缺乏对这些疫苗的免疫原性影响和功效的比较了解。免疫原性对于开发和维持对病原微生物的有效和持久的疫苗接种后免疫力是必不可少的。本系统评价旨在评估和总结基于核酸的抗COVID-19疫苗的免疫原性和保护功效。本审查遵循了系统审查的首选报告项目（PRISMA）建议。CASP工具用于随机对照试验的质量评估。所有纳入的研究均采用随机对照方法，结果表明，有希望的免疫反应和有效性提供了针对COVID-19感染的高水平保护。这项研究为推进疫苗技术提供了重要的见解。此外，它指导制定，告知个性化的疫苗接种策略，并加强全球卫生准备，特别是在疫苗获得有限的地区。
